Finzati - Logo
LIXT logo

Lixte Biotechnology Holdings, Inc.

LIXTBiotechnology
$0.00
0.00 (0.00%)
EarningsLatest report: Mar 31, 2026
WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$88.33M
Growth
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.07Healthy liquidity · 3.88Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 14, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$88.33M
52W Range0.68 - 7.78
Beta1.05
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.07
Current Ratio3.88
Quick Ratio3.88
Volume892.22K

Investment DNA

How strong this company looks for long-term investors

34
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score
Manageable debt level · 0.07Healthy liquidity · 3.88Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 10/25/2007
Industry: Biotechnology
P/B i: 19.69
Debt / Equity i: 0.07
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.07
Current Ratio: 3.88
Quick Ratio: 3.88
Status: Good

Insider Transactions

Recent executive and insider activity

1 high-volume insider sell detected
Porter Stuart D
Transaction: 05/29/2026
OTHER
Change
0
Price
Not reported
Filing
06/01/2026
Type
OTHER
Porter Stuart D
Transaction: 05/29/2026
BUY
Change
+25,000
Price
Not reported
Filing
06/01/2026
Type
BUY
Holloway Michael Andrew
Transaction: 04/15/2026
SELL
Change
-25,000
Price
$3.59
Filing
04/17/2026
Type
SELL